Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours Β· Estimated delivery Aug 15 - Aug 20
Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med .2026
Mineral Deficiencies and Anemia Risk With GLP-1 Drugs The research also points to mineral depletion, not just vitamin issues
Rare heterozygous PCSK1 variants in human obesity: the contribution of the p.Y181H variant and a literature review
Understanding how dosing worksand what constitutes an effective weekly dosehelps patients make informed decisions about their treatment path
Flavour pineapple: water, L-carnitine, taurine, acidity regulator citric acid, pineapple emulsion (flavouring, colourants E 102 and E 110 - may have an adverse effect on activity and attention in children), caffeine, green tea extract (50 % polyphenols, 15 % EGCG epigallocatechin gallate, 8 % caffeine), preservatives potassium sorbate and sodium benzoate, nicotinamide, sweeteners acesulfame K and sucralose, calcium D-pantothenate, sweetener steviol-glycosides, pyridoxine hydrochloride, thiamine hydrochloride, chromium lactate
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
US$ 23.55
US$ 28.14
US$ 26.48
US$ 22.98
US$ 25.49
US$ 25.72
US$ 21.56
US$ 26.77
US$ 24.77
US$ 23.70
